QQQ $ 451.64 $ -1.83 (-0.4 %)
DIA $ 399.14 $ -0.07 (-0.02 %)
SPY $ 528.49 $ -1.29 (-0.24 %)
TLT $ 92.06 $ -0.04 (-0.04 %)
GLD $ 220.06 $ -0.86 (-0.39 %)
$ 0.4
-- x --
-- x --
-- - --
$ 0.35 - $ 0.95
86,843
na
284,587
$ 4.51
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-15-2024 03-31-2024 10-Q
2 03-26-2024 12-31-2023 10-K
3 11-09-2023 09-30-2023 10-Q
4 08-10-2023 06-30-2023 10-Q
5 05-04-2023 03-31-2023 10-Q
6 03-16-2023 12-31-2022 10-K
7 11-10-2022 09-30-2022 10-Q
8 08-15-2022 06-30-2022 10-Q
9 05-12-2022 03-31-2022 10-Q
10 03-24-2022 12-31-2021 10-K
11 11-10-2021 09-30-2021 10-Q
12 08-11-2021 06-30-2021 10-Q
13 05-12-2021 03-31-2021 10-Q
14 03-25-2021 12-31-2020 10-K
15 11-12-2020 09-30-2020 10-Q
16 08-11-2020 06-30-2020 10-Q
17 05-12-2020 03-31-2020 10-Q
18 03-24-2020 12-31-2019 10-K
19 11-13-2019 09-30-2019 10-Q
20 08-13-2019 06-30-2019 10-Q
21 05-14-2019 03-31-2019 10-Q
22 03-22-2019 12-31-2018 10-K
23 11-05-2018 09-30-2018 10-Q
24 08-13-2018 06-30-2018 10-Q
25 05-14-2018 03-31-2018 10-Q
26 03-21-2018 12-31-2017 10-K
27 11-14-2017 09-30-2017 10-Q
28 08-10-2017 06-30-2017 10-Q
29 05-11-2017 03-31-2017 10-Q
30 03-30-2017 12-31-2016 10-K
31 11-10-2016 09-30-2016 10-Q
32 08-11-2016 06-30-2016 10-Q
33 05-12-2016 03-31-2016 10-Q
34 03-08-2016 12-31-2015 10-K
35 11-16-2015 09-30-2015 10-Q
36 08-13-2015 06-30-2015 10-Q
37 05-15-2015 03-31-2015 10-Q
38 03-30-2015 12-31-2014 10-K
39 11-14-2014 09-30-2014 10-Q
40 08-14-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-downgrades-panbela-therapeutics-to-neutral

HC Wainwright & Co. analyst Joseph Pantginis downgrades Panbela Therapeutics (OTC:PBLA) from Buy to Neutral.

 panbela-therapeutics-q1-2024-gaap-eps-228-misses-148-estimate

Panbela Therapeutics (NASDAQ:PBLA) reported quarterly losses of $(2.28) per share which missed the analyst consensus estimate o...

 hc-wainwright--co-maintains-buy-on-panbela-therapeutics-lowers-price-target-to-5

HC Wainwright & Co. analyst Joseph Pantginis maintains Panbela Therapeutics (OTC:PBLA) with a Buy and lowers the price t...

 roth-mkm-maintains-buy-on-panbela-therapeutics-maintains-25-price-target

Roth MKM analyst Jonathan Aschoff maintains Panbela Therapeutics (OTC:PBLA) with a Buy and maintains $25 price target.

 panbela-therapeutics-q4-2023-gaap-eps-6590-misses-2434-estimate

Panbela Therapeutics (NASDAQ:PBLA) reported quarterly losses of $(65.90) per share which missed the analyst consensus estimate ...

 top-4-health-care-stocks-that-are-preparing-to-pump-this-month

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

 panbela-regains-nasdaq-compliance
Panbela Regains Nasdaq Compliance
02/15/2024 13:05:07

 roth-mkm-maintains-buy-on-panbela-therapeutics-adjusts-price-target-to-25

Roth MKM analyst Jonathan Aschoff maintains Panbela Therapeutics (NASDAQ:PBLA) with a Buy, adjusts target to $25 from $500.

 whats-going-on-with-panbela-therapeutics-stock-today

Panbela Therapeutics announced acceptance of SBP-101 abstract for presentation and disclosed details of a public offering, expe...

 panbela-therapeutics-announced-abstract-for-sbp-101-accepted-for-poster-presentation-at-american-association-for-cancer-research

Poster PresentationTitle:  Ivospemin/doxorubicin combination modulates polyamine metabolism to improve survival in murine ovari...

 crude-oil-down-over-1-science-37-holdings-shares-spike-higher

U.S. stocks traded slightly higher toward the end of trading, with the Nasdaq Composite gaining around 75 points on Monday. Th...

 why-panbela-therapeutics-shares-are-trading-lower-by-65-here-are-other-stocks-moving-in-mondays-mid-day-session

Shares of Panbela Therapeutics, Inc. (NASDAQ: PBLA) fell sharply during Monday’s session after the company announced pricing of...

 dow-edges-lower-cardlytics-shares-jump

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining around 20 points on Monday. The Dow traded ...

 us-stocks-edge-higher-amazon-and-irobot-agree-to-terminate-acquisition-deal

U.S. stocks traded slightly higher this morning, with the Dow Jones index gaining around 25 points on Monday. Following the ma...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION